-
AstraZeneca CEO On CNBC (AZN)
Thursday, April 14, 2011 - 7:57am | 14AstraZeneca CEO On CNBC (NYSE: AZN)
-
UPDATE: Goldman Sachs Raising Price Target On Warner Chilcott Ltd. (WCRX)
Thursday, April 14, 2011 - 7:50am | 182Goldman Sachs is raising its price target on shares of Warner Chilcott Ltd. (NASDAQ: WCRX) to $28 from $26, but it has a Neutral rating on shares. In a note to clients, Goldman writes, "We hosted WCRX CFO Paul Herendeen for dinner and came away with greater confidence in our now above consensus...
-
Citigroup Raises PT On Endo Pharmaceuticals To $48
Thursday, April 14, 2011 - 7:36am | 26Citigroup has raised the price target on Endo Pharmaceuticals (NASDAQ: ENDP) from $42 to $48 and maintains its Buy rating.
-
Forest Laboratories Completes Acquisition of Clinical Data
Wednesday, April 13, 2011 - 4:37pm | 49Forest Laboratories, Inc. (NYSE: FRX) today announced that it has successfully completed its acquisition of Clinical Data, Inc. (NASDAQ: CLDA) by means of what is known as a short-form merger under Delaware law.
-
Sanofi-Aventis Seeks Buyer For Its U.S. Dermatology Business - Bloomberg (SNY)
Wednesday, April 13, 2011 - 4:08pm | 22According to Bloomberg, Sanofi-Aventis Seeks Buyer For Its U.S. Dermatology Business (NYSE: SNY)
-
Watson Pharmaceuticals Hits 52-Week High (WPI)
Wednesday, April 13, 2011 - 2:44pm | 34Watson Pharmaceuticals (NYSE: WPI) has hit a 52-week high in today's trading. At last check, the year-to-date performance of Watson Pharmaceuticals has been a gain of 13.9%.
-
Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets (PRGO, TEVA)
Wednesday, April 13, 2011 - 2:19pm | 81Perrigo (NASDAQ: PRGO) today announced that its partner, Teva Pharmaceutical Industries (NASDAQ: TEVA), has received final OTC approval to sell and distribute fexofenadine HCl 60 mg and 180 mg tablets; the generic equivalents of Sanofi-Aventis' Allegra 60 mg and 180 mg products. Teva has had Rx...
-
Biotech/Pharma Stock News; BioSante Pharmaceuticals Announces Teva New Drug Application for Bio-T-Gel™
Wednesday, April 13, 2011 - 12:08pm | 765LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva...
-
New Clinical Studies Reinforce the LAP-BAND System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity (AGN)
Wednesday, April 13, 2011 - 9:04am | 106Two new studies published in the current issue of Surgery for Obesity and Related Diseases, a peer-reviewed journal, add to the large body of scientific evidence which supports that the LAP-BAND Adjustable Gastric Banding System, made by Allergan, Inc. (NYSE: AGN), is a safe and effective weight-...
-
Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Teva New Drug Application for Bio-T-Gel
Wednesday, April 13, 2011 - 9:00am | 49LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva...
-
Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Teva New Drug Application for Bio-T-Gel
Wednesday, April 13, 2011 - 9:00am | 49LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva...
-
Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel
Wednesday, April 13, 2011 - 9:00am | 50LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) reports a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of...
-
Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Teva New Drug Application (NDA) for Testosterone Gel, Bio-T-Gel
Wednesday, April 13, 2011 - 9:00am | 50LINCOLNSHIRE, Ill. - April 13, 2011 (Investorideas.com newswire) - Pharma stock news; BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) reports a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of...
-
Stifel Nicolaus Summary
Wednesday, April 13, 2011 - 8:32am | 83Stifel Nicolaus is upgrading iStar Financial (NYSE: SFI) to Buy. It is also upgrading Newcastle Investment (NYSE: NCT) to Buy. It is increasing the target price on Endo Pharmaceuticals (NASDAQ: ENDP) to $53.00 from $45.00. Estimates are increased on iStar Financial and Newcastle Investment, and...
-
Benzinga's Top Upgrades (GTXI, PRGO, RVBD, ITMN)
Wednesday, April 13, 2011 - 8:24am | 128GTx Inc (NASDAQ: GTXI) was upgraded by Citigroup from "hold" to "buy." GTXI's shares closed at $2.75 yesterday. GTXI's trailing-twelve-month profit margin is 25.23%. Goldman upgraded Perrigo Company (NASDAQ: PRGO) from “sell” to “neutral.” PRGO's shares closed at $85.40 yesterday. Perrigo's...